Comparative Pharmacology
Head-to-head clinical analysis: ARISTOCORT A versus DECADRON W XYLOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOCORT A versus DECADRON W XYLOCAINE.
ARISTOCORT A vs DECADRON W/ XYLOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, suppress cytokine production, and decrease inflammation and immune responses.
Dexamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response. Lidocaine is a sodium channel blocker that stabilizes neuronal membranes, inhibiting nerve impulse initiation and conduction, producing local anesthesia.
Intralesional injection: 2.5-5 mg per lesion, repeated every 1-2 weeks. Topical: Apply thin film to affected area 2-4 times daily.
Not a standard pre-mixed combination; individual components dosed separately. Dexamethasone: 0.5-9 mg/day oral/IV divided every 6-12h. Lidocaine: 1-5 mg/kg IV bolus (max 300 mg), then 1-4 mg/min IV infusion; or local infiltration up to 4.5 mg/kg (max 300 mg) with epinephrine.
None Documented
None Documented
Terminal half-life: 2-3 hours for triamcinolone acetonide. Clinical context: Duration of action longer due to receptor binding and intracellular activity; anti-inflammatory effects persist 24-48 hours after IM administration.
Dexamethasone: 3-4 hours (short-acting steroid). Lidocaine: 1.5-2 hours (prolonged in heart failure/hepatic disease).
Renal: 75% as metabolites (primarily conjugated), 15% as unchanged drug. Biliary/fecal: 10%.
Dexamethasone: Renal (~65% as metabolites, <10% unchanged); Biliary/Fecal (<35%). Lidocaine: Hepatic metabolism to MEGX; Renal (<10% unchanged).
Category C
Category C
Corticosteroid
Corticosteroid/Local Anesthetic Combination